Table 2.

Univariate and multivariate analyses for decline in eGFR (eGFR based on CKD-EPI equation), ESRD, and death for HIV+ CCC individuals, 1998 through 2005

Baseline Group (N)OutcomeEvents, nUnadjusted Incidence Rate Ratio AA:non-AA (95% CIs)cAdjusted HR AA:non-AA (95% CIs)c
Total populationa (2468)eGFR decline and death1821.9 (1.4, 2.5)1.6 (1.1, 2.3)
eGFR decline632.1 (1.3, 3.5)1.1 (0.6, 2.1)
death1261.7 (1.2, 2.4)1.5 (0.9, 2.5)
CKD5/ESRDd214.9 (1.9, 12.2)4.5 (1.8, 11.4)
Subgroup analysisa eGFR ≥60 ml/min per 1.73 m2 (2366)eGFR decline and death1551.6 (1.2, 2.2)1.2 (0.8, 1.9)
eGFR decline561.6 (0.9, 2.9)1.1 (0.5, 2.2)
death1151.6 (1.1, 2.3)1.4 (0.8, 2.3)
Subgroup analysisb eGFR <60 ml/min per 1.73 m2 (102)eGFR decline and death273.0 (1.4, 6.7)1.8 (0.5, 6.1)b
eGFR decline173.2 (1.2, 8.8)2.5 (0.9, 6.9)b
death111.8 (0.5, 5.7)1.9 (0.6, 6.5)b
  • Race categorized as HIV+ AA and HIV+ non-AA. HRs reported for AA referent to non-AA.

  • a Total population and eGFR ≥60 ml/min per 1.73 m2 subgroups adjusted for the following baseline covariates: age, absolute CD4 count, HIV-1 RNA, baseline eGFR, race, gender, hypertension, anemia, HAART use, hepatitis C, cardiovascular disease, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, diabetes, intravenous drug use–HIV risk, and opportunistic infection/AIDS-defining event.

  • b All other subgroup analyses based on univariate Cox model due to a small sample size and limited power.

  • c 95% CIs reported for the corresponding HR using Cox regression.

  • d CKD5 defined as eGFR ≤15 to 29 ml/min per 1.73 m2; ESRD <15 ml/min per 1.73 m2 or by ICD-9 code.